Generation of self-renewing neuromesodermal progenitors with neuronal and skeletal muscle bipotential from human embryonic stem cells DOI Creative Commons

Pingxin Sun,

Yuan Yuan,

Zhuman Lv

и другие.

Cell Reports Methods, Год журнала: 2024, Номер 4(11), С. 100897 - 100897

Опубликована: Ноя. 1, 2024

Язык: Английский

Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient DOI
Shusen Wang, Yuanyuan Du, Boya Zhang

и другие.

Cell, Год журнала: 2024, Номер 187(22), С. 6152 - 6164.e18

Опубликована: Сен. 25, 2024

Язык: Английский

Процитировано

49

A rapid chemical reprogramming system to generate human pluripotent stem cells DOI
Yanglu Wang,

Fangqi Peng,

Zhihan Yang

и другие.

Nature Chemical Biology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 3, 2025

Язык: Английский

Процитировано

4

H3K27me3-mediated epigenetic regulation in pluripotency maintenance and lineage differentiation DOI Creative Commons
Liwen Jiang, Linfeng Huang, Wei Jiang

и другие.

Cell Insight, Год журнала: 2024, Номер 3(4), С. 100180 - 100180

Опубликована: Июнь 27, 2024

Cell fate determination is an intricate process which orchestrated by multiple regulatory layers including signal pathways, transcriptional factors, epigenetic modifications, and metabolic rewiring. Among the sophisticated modulations, repressive mark H3K27me3, deposited PRC2 (polycomb complex 2) removed demethylase KDM6, plays a pivotal role in mediating cellular identity transition through its dynamic precise alterations. Herein, we overview discuss how H3K27me3 modifiers regulate pluripotency maintenance early lineage differentiation. We primarily highlight following four aspects: 1) two subcomplexes PRC2.1 PRC2.2 distribution of genomic H3K27 methylation; as critical regulator exit; 3) emerging eraser KDM6 differentiation; 4) newly identified additional factors influencing H3K27me3. present comprehensive insight into molecular principles regulation well this participates pluripotent stem cell-centered cell determination.

Язык: Английский

Процитировано

6

Patient-derived induced pluripotent stem cell organoids for amyotrophic lateral sclerosis drug discovery DOI Creative Commons
Wenyan Li,

Jinqi Liu,

Wenting Li

и другие.

Acta Materia Medica, Год журнала: 2025, Номер 4(1)

Опубликована: Янв. 1, 2025

Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the development of effective treatments. Given these challenges, reliable disease models that accurately replicate ALS phenotypes with relevant underpinnings are essential advancing precision medicine in ALS. Patient-derived induced pluripotent stem cell (iPSC) organoids have emerged as an innovative tool modeling drug evaluation. Growing evidence highlights advantages replicating supporting development. However, challenges remain utilizing testing other neurodegenerative diseases. In this review we summarize current progress model development, encompassing both vitro vivo non-human models, well iPSC-derived human models. Furthermore, within context screening, discuss critical considerations applying to evaluate disease-associated reflect disease-related symptoms.

Язык: Английский

Процитировано

0

Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects DOI Creative Commons
Arthur Rech Tondin, Giacomo Lanzoni

BioDrugs, Год журнала: 2025, Номер unknown

Опубликована: Фев. 7, 2025

Язык: Английский

Процитировано

0

Transplantation of Chemically Induced Human Fibroblast-Derived Cells Enhances Functional Recovery in a Common Marmoset Model of Spinal Cord Injury DOI Open Access

Toshihiro Kurahashi,

Chiyoko Nishime,

Eiko Nishinaka

и другие.

ACTA HISTOCHEMICA ET CYTOCHEMICA, Год журнала: 2025, Номер 58(1), С. 19 - 30

Опубликована: Фев. 26, 2025

Spinal cord injury (SCI) is incurable and often leads to permanent motor dysfunction, paralysis, sensory impairment. We previously developed a method directly reprogram human fibroblasts into neuron-like cells using only chemical compounds. In rat model of SCI, we transplanted chemically reprogrammed cells, termed immature chemical-induced (CiN) derived the with slight modifications found that CiN exhibited therapeutic efficacy in SCI. As primate models more closely mimic humans than models, experiments are required accurately assess safety before their use humans. Therefore, this study, aimed determine cell transplantation marmoset SCI model. Immature were subacute on Day 9 after contusion injury, was assessed. Motor recovery assessed based spontaneous activity original open-field rating scale over six weeks, which spinal at site subjected histopathological MRI analyses. Animals significantly enhanced compared control animals, consistent improved nerve or preservation. Our findings suggest can effectively treat primates.

Язык: Английский

Процитировано

0

Direct fibroblast reprogramming: an emerging strategy for treating organic fibrosis DOI Creative Commons

Haohui Lin,

Xia Wang, Manhon Chung

и другие.

Journal of Translational Medicine, Год журнала: 2025, Номер 23(1)

Опубликована: Фев. 27, 2025

Direct reprogramming has garnered considerable attention due to its capacity directly convert differentiated cells into desired cells. Fibroblasts are frequently employed in studies their abundance and accessibility. However, they also the key drivers progression of fibrosis, a pathological condition characterized by excessive extracellular matrix deposition tissue scarring. Furthermore, initial stage typically involves deactivating fibrotic pathways. Hence, direct offers valuable method regenerate target for repair while simultaneously reducing tendencies. Understanding link between fibrosis could help develop effective strategies treat damaged with potential risk fibrosis. This review summarizes advances reveals anti-fibrosis effects various organs such as heart, liver, skin. we dissect mechanisms influenced molecules including TGF-β signaling, mechanical inflammation epigenetic modifiers, metabolic regulators. Innovative methods fibroblast like small molecules, CRISPRa, modified mRNA, challenges cellular heterogeneity senescence faced vivo reprogramming, discussed.

Язык: Английский

Процитировано

0

Advancing type 1 diabetes treatment: a breakthrough in stem cell therapy DOI

Zainab Anfaal,

Zia Ullah Khan

Diabetes & Metabolism, Год журнала: 2025, Номер unknown, С. 101635 - 101635

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0

Pluripotent Stem Cells: Recent Advances and Emerging Trends DOI Creative Commons
Aline Yen Ling Wang, Ana Elena Aviña, Yen‐Yu Liu

и другие.

Biomedicines, Год журнала: 2025, Номер 13(4), С. 765 - 765

Опубликована: Март 21, 2025

The field of induced pluripotent stem cells (iPSCs) continues to evolve, offering unprecedented potential for regenerative medicine, disease modeling, and therapeutic applications [...]

Язык: Английский

Процитировано

0

Decoding human chemical reprogramming: mechanisms and principles DOI
Lin Cheng, Yanglu Wang, Jingyang Guan

и другие.

Trends in Biochemical Sciences, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0